NO950626L - Agent for transdermal application containing 3-ketodesogestrel - Google Patents

Agent for transdermal application containing 3-ketodesogestrel

Info

Publication number
NO950626L
NO950626L NO950626A NO950626A NO950626L NO 950626 L NO950626 L NO 950626L NO 950626 A NO950626 A NO 950626A NO 950626 A NO950626 A NO 950626A NO 950626 L NO950626 L NO 950626L
Authority
NO
Norway
Prior art keywords
agent
ketodesogestrel
transdermal application
application containing
transdermal
Prior art date
Application number
NO950626A
Other languages
Norwegian (no)
Other versions
NO307325B1 (en
NO950626D0 (en
Inventor
Ralph Lipp
Clemens Gunther
Jutta Riedl
Ulrich Tauber
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO950626D0 publication Critical patent/NO950626D0/en
Publication of NO950626L publication Critical patent/NO950626L/en
Publication of NO307325B1 publication Critical patent/NO307325B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A transdermal application agent is characterized in that it contains 3-keto-desogestrel, if required combined with one or two estrogens.
NO950626A 1992-08-21 1995-02-20 Agent for transdermal application containing 3-ketodesogestrel NO307325B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4227989A DE4227989A1 (en) 1992-08-21 1992-08-21 Agent for transdermal application containing 3-keto-desogestrel
PCT/EP1993/002224 WO1994004157A1 (en) 1992-08-21 1993-08-19 Transdermal application agent containing 3-keto-desogestrel

Publications (3)

Publication Number Publication Date
NO950626D0 NO950626D0 (en) 1995-02-20
NO950626L true NO950626L (en) 1995-02-20
NO307325B1 NO307325B1 (en) 2000-03-20

Family

ID=6466236

Family Applications (1)

Application Number Title Priority Date Filing Date
NO950626A NO307325B1 (en) 1992-08-21 1995-02-20 Agent for transdermal application containing 3-ketodesogestrel

Country Status (13)

Country Link
EP (1) EP0655916B1 (en)
JP (1) JPH08500584A (en)
AT (1) ATE162945T1 (en)
AU (1) AU687013B2 (en)
CA (1) CA2141690A1 (en)
DE (2) DE4227989A1 (en)
DK (1) DK0655916T3 (en)
ES (1) ES2115071T3 (en)
FI (1) FI950774A (en)
GR (1) GR3026627T3 (en)
HU (1) HUT69406A (en)
NO (1) NO307325B1 (en)
WO (1) WO1994004157A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9408457A (en) * 1993-12-27 1997-08-05 Akzo Nobel Nv Percutaneous pharmaceutical preparation
AU5971294A (en) * 1994-01-27 1995-08-15 Schering Aktiengesellschaft Agent, intended for transdermal administration, containing 14alpha,17alpha-ethanoestra-1,3,5(10)-triene-3,17beta -diol
DE4405899A1 (en) * 1994-02-18 1995-08-24 Schering Ag Agent for transdermal application containing desogestrel
DK0836506T4 (en) * 1995-06-07 2012-01-30 Ortho Mcneil Pharm Inc Transdermal patch for administration of 17-deacetyl norgestimate alone or in combination with an estrogen
JPH11509222A (en) * 1995-07-17 1999-08-17 シェリング アクチェンゲゼルシャフト Agent for transdermal administration comprising an ester of 13-ethyl-17β-hydroxy-11-methylene-18,19-dinor-17α-pregn-4-en-20-yn-3-one
FR2749514B1 (en) * 1996-06-11 1998-08-07 Hoechst Marion Roussel TRANSDERMAL SYSTEMS CONTAINING 2 ACTIVE INGREDIENTS IN SEPARATE COMPARTMENTS, THEIR PREPARATION METHOD AND THEIR APPLICATION AS A MEDICAMENT
KR100496109B1 (en) * 1996-06-11 2005-09-09 아벤티스 파마 소시에떼아노님 Transdermal Systems Containing Two Active principles in Separate Compartments, Their Method of Preparation and Application as Medicine
DE19629468A1 (en) * 1996-07-11 1998-01-15 Schering Ag Transdermal therapeutic systems
US6987101B1 (en) * 1996-12-20 2006-01-17 Schering Aktiengesellschaft Therapeutic gestagens for the treatment of premenstrual dysphoric disorder
EP1041982B1 (en) 1997-12-22 2011-10-19 Bayer HealthCare LLC INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS
TR200002593T2 (en) * 1998-03-09 2000-12-21 Akzo Nobel N.V. A new contraception kit
WO2000009136A1 (en) * 1998-08-11 2000-02-24 Akzo Nobel N.V. Progestogen-only contraceptive kit providing good cycle control
ATE556713T1 (en) 1999-01-13 2012-05-15 Bayer Healthcare Llc OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS P38 KINASE INHIBITORS
US20020065296A1 (en) 1999-01-13 2002-05-30 Bayer Corporation Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
US6787531B1 (en) 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
NZ517845A (en) 1999-08-31 2004-12-24 Schering Ag Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
EP2305267A3 (en) 1999-08-31 2011-08-17 Bayer Schering Pharma Aktiengesellschaft Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
WO2003047579A1 (en) 2001-12-03 2003-06-12 Bayer Pharmaceuticals Corporation Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
AU2003209116A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
TW200400041A (en) * 2002-05-30 2004-01-01 Akzo Nobel Nv Use of new etonogestrel esters
TW200403065A (en) * 2002-05-30 2004-03-01 Akzo Nobel Nv New etonogestrel esters
FR2848112B1 (en) * 2002-12-10 2007-02-16 Besins Int Belgique PHARMACEUTICAL COMPOSITION FOR TRANSDERMAL OR TRANSMUCTIVE DELIVERY COMPRISING AT LEAST ONE PROGESTATIVE AND / OR AT LEAST ONE OESTROGEN, PREPARATION METHOD AND USES THEREOF
WO2004054544A1 (en) * 2002-12-10 2004-07-01 Besins International Belgique Pharmaceutical composition for transdermal or transmucous administration comprising a progestin or an estrogen, method for preparing same and uses thereof
FR2851470B1 (en) 2003-02-20 2007-11-16 Besins Int Belgique PHARMACEUTICAL COMPOSITION FOR TRANSDERMAL OR TRANSMUCTIVE DELIVERY
JP2009501722A (en) * 2005-07-15 2009-01-22 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト Drospirenone-containing transdermal drug supply device and method for supplying the same
CN101287470B (en) 2005-10-12 2012-10-17 优尼麦德药物股份有限公司 Improved testosterone gel and method of use
US20090068146A1 (en) 2005-10-31 2009-03-12 Scott Wilhelm Diaryl ureas and combinations
MX2008014953A (en) 2006-05-26 2009-03-05 Bayer Healthcare Llc Drug combinations with substituted diaryl ureas for the treatment of cancer.
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
TW200840595A (en) * 2006-12-12 2008-10-16 Organon Nv Oral contraceptive spray
US8148532B2 (en) 2007-03-14 2012-04-03 Guoqing Paul Chen Spiro substituted compounds as angiogenesis inhibitors
US8246978B2 (en) * 2007-07-10 2012-08-21 Agile Therapeutics, Inc. Dermal delivery device with reduced loss of its volatile components
US8211911B2 (en) 2008-08-19 2012-07-03 Guoqing Paul Chen Compounds as kinase inhibitors
US10080760B2 (en) 2009-10-27 2018-09-25 Besins Healthcare Luxembourg Sarl Transdermal pharmaceutical compositions comprising active agents
EP2595628A1 (en) 2010-07-19 2013-05-29 Bayer HealthCare LLC Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3333240A1 (en) * 1983-09-12 1985-03-28 Schering AG, 1000 Berlin und 4709 Bergkamen MEDIUM FOR TRANSDERMAL APPLICATION OF MEDICINAL PRODUCTS
DK174724B1 (en) * 1986-07-15 2003-10-06 Wyeth Corp Use of a composition comprising an estrogen and a progestogen for the preparation of a dosage form to provide hormone replacement therapy and contraception for women during the premenopause and pack to provide the composition
CN1021196C (en) * 1986-12-29 1993-06-16 新泽西州州立大学(鲁杰斯) Prepn. method of progestin unit and system
IE62665B1 (en) * 1990-12-17 1995-02-22 Akzo Nv Contraceptive regimen
IE71202B1 (en) * 1990-12-17 1997-02-12 Akzo Nv Progestagen-only contraceptive

Also Published As

Publication number Publication date
HU9500510D0 (en) 1995-04-28
GR3026627T3 (en) 1998-07-31
NO307325B1 (en) 2000-03-20
WO1994004157A1 (en) 1994-03-03
FI950774A0 (en) 1995-02-20
CA2141690A1 (en) 1994-03-03
DE4227989A1 (en) 1994-06-09
NO950626D0 (en) 1995-02-20
FI950774A (en) 1995-02-20
DK0655916T3 (en) 1998-09-23
ES2115071T3 (en) 1998-06-16
JPH08500584A (en) 1996-01-23
AU687013B2 (en) 1998-02-19
DE59308124D1 (en) 1998-03-12
EP0655916A1 (en) 1995-06-07
AU4950493A (en) 1994-03-15
ATE162945T1 (en) 1998-02-15
HUT69406A (en) 1995-09-28
EP0655916B1 (en) 1998-02-04

Similar Documents

Publication Publication Date Title
NO950626L (en) Agent for transdermal application containing 3-ketodesogestrel
AU4374789A (en) Gestodene-containing agent for transdermal administration
NO874971L (en) IMPROVED METAL CONTAINING DIAGNOSTIC AGENT.
DE69112372D1 (en) Planetary mixer.
NO911234D0 (en) FATABLE ACTIVATOR EVENT.
NO911088D0 (en) SURFACTANT FOR GASED EMULSUM EXPLOSIVES.
TR199802351T2 (en) Anti-vaginitis composition containing one or more local anesthetics and anti-vaginitis agents for topical use.
ES458559A1 (en) Cosmetic composition for the skin
CH684234GA3 (en) Muslim calendar.
DK383183D0 (en) BIOCID, NON-FUNGICID AND / OR BACTERICID, AGENT AND THIOSEMIC CARBONZONE AND METAL COMPLEXES THEREOF FOR USE IN THE AGENT
NO963433L (en) Agent for transdermal application containing desogestrel
NO841645L (en) DEVICE, SPECIFICALLY APPLICABLE AS DIFFERENTIAL BRAKE AND DIFFERENTIAL LOCK.
IE791212L (en) 2- azaergolines and 2 - aza -8 (or9)- ergolines
TR199802703T2 (en) Use of combinations containing Vx478, Zidovidin, and/or 1592U89 in the treatment of HIV.
DE58907277D1 (en) Housing for calendar sheets or the like
NO963128D0 (en) Agent for Transdermal Application Containing 14,17-Ethano-Ostra-1,3,5 (10) -Trien-3,17-Diol
AU2149977A (en) Injectable male sterilant for selectively controlling the function ofthe testes
UA6775A (en) Calefacient composition for skin application
JPS5287155A (en) Steroid derivatives and pharmaceutical agent having cortisone action
ATA211992A (en) PAD FOR SCHOOL AND THE LIKE
KR950006270U (en) Convenient envelope with fine perforation lines
SU646705A1 (en) Device for defusing and oxidizing substrates
ES1023013U (en) Scissors permanent adjustment. (Machine-translation by Google Translate, not legally binding)
MX9203759A (en) STEROIDAL 5-ALPHA-REDUCTASE INHIBITORS.
ES1016779Y (en) DESKTOP CALENDAR.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees

Free format text: LAPSED IN FEBRUARY 2002